Qiagen announces newly published data supporting efficacy of QuantiFERON

QIAGEN (QGEN) N.V. “announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus blood test for detecting tuberculosis infection, particularly in immunocompromised and other high-risk populations. A study recently published in BMC Public Health evaluated TB infection screening strategies among adults living with HIV in Thailand and found that QFT-Plus testing reduced the modeled lifetime risk of progression to active TB by 41% compared with the tuberculin skin test, while also lowering overall lifetime healthcare costs. More accurate detection of TB infection can help clinicians initiate preventive therapy earlier and support more efficient use of healthcare resources. This study builds on a strong and expanding body of clinical data supporting the use of QFT-Plus across diverse patient populations. More than 2,500 published studies have demonstrated the test’s performance, with over 125 million QuantiFERON-TB tests used worldwide, including in populations at increased risk of developing active TB disease such as those receiving immunosuppressive therapies. Accurate detection of TB infection in these groups remains critical to enable timely preventive treatment and reduce the risk of disease progression.”